You are here

TOPIC 353: HIGHLY ACCURATE LOW COST CTDNA DIAGNOSTICS WITH MAGNETIC NANOPARTICLE ENABLED AUTOMATED SAMPLE PREP - MOONSHOT

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91019C00035
Agency Tracking Number: N44CA190035
Amount: $1,999,962.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
942 RICH PL
MOUNTAIN VIEW, CA 94040-2477
United States
DUNS: 966369048
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Aihua Fu
 (408) 505-9232
 aihuafu@nvigen.com
Business Contact
 Aihua Fu
Phone: (408) 505-9232
Email: aihuafu@nvigen.com
Research Institution
N/A
Abstract

The goal of the research is to develop a highly accurateautomatedand low cost ctDNA test to monitor efficacy of treatment of metastatic breast cancer patients by identifying the emergence of certain DNA mutations in plasma samplesThere is growing evidence that the presence of certain DNA mutations in the blood stream correlates with breast cancer becoming resistance to hormone treatmentNVIGEN will develop a test that can detect the emergence of these DNA mutations early enough so that Physicians can prescribe a more effective treatment to improve patient outcomeThe test involves captureing DNA from the plasma portion of blood samples using NVIGEN s proprietary molecularly engineered magnetic nanoparticles combined with highly sensitive target enrichment of specific DNA mutation in an automated workflowDuring the proposed programNVIGEN will optimize the workflowconfirm the test s ability to detect multiple relevant DNA mutationsand conduct clinical validations to verify that the DNA mutations detected by the test correlate with efficacy of treatment providing a basis for physicians to select more effective treatments for breast cancer patientsThis test will not only help breast cancer patients but the technology can also be extended for a broad range of other cancer types

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government